linkedin post 2013-03-21 07:01:46

Uncategorized
CATALUNYA IS THE CALIFORNIA OF EUROPE. In both places we see remarkable parallels: The innovative entrepreneurial spirit is alive and well; young people are full of energy and optimism about changing the world by entrepreneuring; the weather is spectacular; the terrain is extraordinary with dramatic mountains and idyllic coastal locations; the foodie culture is big; local wines are splendid; they are big "must-see" regions on all Bucket Lists. Truly, both locations are very special places to live and work, rich in culture and beauty. View in LinkedIn
Read More

linkedin post 2013-03-22 06:27:55

Uncategorized
THE LONDON AIM MARKET was started in 1995, and since then Tokyo, Madrid and a number of other countries (including Ghana) have started similar initiatives. The less demanding stock registration criteria and reporting requirements make these alternative sources (of often thinly traded stocks) an alternative venue for some companies to raise capital. Worldwide, there are a number of small stock market venues with differing rules. While not for everybody, these options are worthy of consideration. View in LinkedIn
Read More

linkedin post 2013-03-22 06:47:54

Uncategorized
TAIWAN HAS LONG BEEN ATTRACTING BIOPHARMA COMPANIES, in an effort to be part of the leadership ranks of biological medicines. In addition to tax incentives, it recently unveiled a 1.9 Bn USD venture fund. The country realized a long time ago that computer chip manufacturing was likely to move to lower cost countries, and initiated bold efforts to attract Bio pharma companies. With a transparent IP culture, a new corporate leadership that has been largely US educated, and a westward looking attitude, this can-do culture has built attractive Bioclusters. View in LinkedIn
Read More

linkedin post 2013-03-22 06:57:27

Uncategorized
TAIWAN IS A GREAT PLACE TO SET UP A COMPANY. With a large percent of GDP devoted to education, a smart and hard-working labor force, and pro-business government, it has a lot to offer. I have been back and forth a dozen times, and Impax Labs (whose board I serve on) has built a huge manufacturing plant in Taiwan. Early in the company's life they raised large amounts of capital from local VCs, and have enjoyed tax incentives for the factory. Only a generation ago, Taiwan was poor, but has been an Asian Tiger, and a model of the economically possible for China. View in LinkedIn
Read More

linkedin post 2013-03-22 07:10:39

Uncategorized
BIOLOGIC DRUGS WILL GENERATE 160 BN USD IN WORLDWIDE SALES IN 2013, and be 50% of new drug approvals in the US in coming years. Most are monoclonal antibodies. Caesar Milstein of the Cambridge University MRC Unit invented monoclonals. A framed letter on his office wall was the irritated response to his request to the MRC for a patent. It suggested that Dr. Milstein stop pestering them with these foolish requests. Needless to say, this was an historic blunder by this beleaguered licensing officer. View in LinkedIn
Read More

linkedin post 2013-03-22 11:50:02

Uncategorized
HARVARD AND SONY DEVELOP HUMAN ORGANS ON CHIPS, as a means for relevant drug testing. By using homogeneous patient samples, with specific mutations that respond to a drug, and eventually use this disease subtype in clinical trials to gain greater chance of success.. Rather than starting with animal testing, which is often misleading, this approach is more promising. On a second application, it may help path the way to grow organs fir human transplantation in years to come. http://lnkd.in/6--xGa View in LinkedIn
Read More

linkedin post 2013-03-22 16:58:35

Uncategorized
DIVIDING THE EQUITY PIE IN A STARTUP has as many contrarian opinions as authors. This read summarizes some of them. At the end of the day, there is no formula, and each decision must be customized to the local situation. Take in these views and make up your own mind. http://lnkd.in/QvWxhn View in LinkedIn
Read More

linkedin post 2013-03-22 18:15:27

Uncategorized
THE EU DRUG AGENCY AND POLICY GROUP DVELOP INITIATIVES TO BOOST ANTIBIOTIC development and research in response to the alarm calls about antibiotic resistant strains. While big Pharma may find the market too small, these markets could still be attractive for SME companies, especially if the government sweetened the pie with longer exclusivity like in the US, or tax credits for research spent. http://lnkd.in/yUzPjw View in LinkedIn
Read More

linkedin post 2013-03-22 18:46:31

Uncategorized
ADVentura Capital is up and running now" "" "We will be organizing monthly BIOBASH drinks and nibbles events, with a speaker at THE GILD INTERNATIONAL in BCN at 5 Permanayer, off Psg De Gracia, it will have a small fee to cover costs only. This is to fill a void we have often heard articulated, and allow people to meet and mix. Dates and times will be posted here. We hope to see you all at these events! View in LinkedIn
Read More